Eisai Ltd., of Woodcliff Lake, N.J., said its epilepsy drug, Fycompa (perampanel), has been granted marketing clearance by European regulators for use as a once-daily, adjunctive therapy for primary generalized tonic-clonic seizures in adults and adolescents (ages 12 and older ) with idiopathic generalized epilepsy.